Cargando…

Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?

Kidney transplantation is the treatment of choice in end-stage renal disease. The main issue which does not allow to utilize it fully is the number of organs available for transplant. Introduction of highly effective oral direct-acting antivirals (DAAs) to the treatment of chronic hepatitis C virus...

Descripción completa

Detalles Bibliográficos
Autores principales: Czarnecka, Paulina, Czarnecka, Kinga, Tronina, Olga, Baczkowska, Teresa, Durlik, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920354/
https://www.ncbi.nlm.nih.gov/pubmed/35260039
http://dx.doi.org/10.1080/0886022X.2022.2047069
_version_ 1784669108766244864
author Czarnecka, Paulina
Czarnecka, Kinga
Tronina, Olga
Baczkowska, Teresa
Durlik, Magdalena
author_facet Czarnecka, Paulina
Czarnecka, Kinga
Tronina, Olga
Baczkowska, Teresa
Durlik, Magdalena
author_sort Czarnecka, Paulina
collection PubMed
description Kidney transplantation is the treatment of choice in end-stage renal disease. The main issue which does not allow to utilize it fully is the number of organs available for transplant. Introduction of highly effective oral direct-acting antivirals (DAAs) to the treatment of chronic hepatitis C virus infection (HCV) enabled transplantation of HCV viremic organs to naive recipients. Despite an increasing number of reports on the satisfying effects of using HCV viremic organs, including kidneys, they are more often rejected than those from HCV negative donors. The main reason is the presence of HCV viremia and not the quality of the organ. The current state of knowledge points to the fact that a kidney transplant from an HCV nucleic acid testing positive (NAT+) donor to naive recipients is an effective and safe solution to the problem of the insufficient number of organs available for transplantation. It does not, however, allow to draw conclusions as to the long-term consequence of such an approach. This review analyzes the possibilities and limitations of the usage of HCV NAT + donor organs. Abbreviations: DAA: direct-acting antivirals; HCV: hepatitis C virus; NAT: nucleic acid testing; OPTN: Organ Procurement and Transplantation Network; KDIGO: Kidney Disease: Improving Global Outcomes; Ab: antigen; eGFR: estimated glomerular filtration rate; D: donor; R: recipient; CMV: cytomegalovirus; HBV: hepatitis B virus; UNOS: United Network for Organ Sharing; PHS: Public Health Service; EBR/GZR: elbasvir/grazoprevir; SVR: sustained virologic response; RAS: resistance-associated substitutions; SOF: soforbuvir; GLE/PIB: glecaprevir/pibrentasvir; ACR: acute cellular rejection; AR: acute rejection; DSA: donor-specific antibodies; KTR: kidney transplant recipients; AASLD: American Association for the Study of Liver Disease; IDSA: Infectious Diseases Society of America; PPI: proton pump inhibitors; CKD: chronic kidney disease; GN: glomerulonephritis; KAS: The Kidney Allocation system
format Online
Article
Text
id pubmed-8920354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-89203542022-03-15 Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? Czarnecka, Paulina Czarnecka, Kinga Tronina, Olga Baczkowska, Teresa Durlik, Magdalena Ren Fail State-of-the-Art Review Kidney transplantation is the treatment of choice in end-stage renal disease. The main issue which does not allow to utilize it fully is the number of organs available for transplant. Introduction of highly effective oral direct-acting antivirals (DAAs) to the treatment of chronic hepatitis C virus infection (HCV) enabled transplantation of HCV viremic organs to naive recipients. Despite an increasing number of reports on the satisfying effects of using HCV viremic organs, including kidneys, they are more often rejected than those from HCV negative donors. The main reason is the presence of HCV viremia and not the quality of the organ. The current state of knowledge points to the fact that a kidney transplant from an HCV nucleic acid testing positive (NAT+) donor to naive recipients is an effective and safe solution to the problem of the insufficient number of organs available for transplantation. It does not, however, allow to draw conclusions as to the long-term consequence of such an approach. This review analyzes the possibilities and limitations of the usage of HCV NAT + donor organs. Abbreviations: DAA: direct-acting antivirals; HCV: hepatitis C virus; NAT: nucleic acid testing; OPTN: Organ Procurement and Transplantation Network; KDIGO: Kidney Disease: Improving Global Outcomes; Ab: antigen; eGFR: estimated glomerular filtration rate; D: donor; R: recipient; CMV: cytomegalovirus; HBV: hepatitis B virus; UNOS: United Network for Organ Sharing; PHS: Public Health Service; EBR/GZR: elbasvir/grazoprevir; SVR: sustained virologic response; RAS: resistance-associated substitutions; SOF: soforbuvir; GLE/PIB: glecaprevir/pibrentasvir; ACR: acute cellular rejection; AR: acute rejection; DSA: donor-specific antibodies; KTR: kidney transplant recipients; AASLD: American Association for the Study of Liver Disease; IDSA: Infectious Diseases Society of America; PPI: proton pump inhibitors; CKD: chronic kidney disease; GN: glomerulonephritis; KAS: The Kidney Allocation system Taylor & Francis 2022-03-09 /pmc/articles/PMC8920354/ /pubmed/35260039 http://dx.doi.org/10.1080/0886022X.2022.2047069 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle State-of-the-Art Review
Czarnecka, Paulina
Czarnecka, Kinga
Tronina, Olga
Baczkowska, Teresa
Durlik, Magdalena
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
title Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
title_full Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
title_fullStr Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
title_full_unstemmed Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
title_short Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
title_sort utilization of hcv viremic donors in kidney transplantation: a chance or a threat?
topic State-of-the-Art Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920354/
https://www.ncbi.nlm.nih.gov/pubmed/35260039
http://dx.doi.org/10.1080/0886022X.2022.2047069
work_keys_str_mv AT czarneckapaulina utilizationofhcvviremicdonorsinkidneytransplantationachanceorathreat
AT czarneckakinga utilizationofhcvviremicdonorsinkidneytransplantationachanceorathreat
AT troninaolga utilizationofhcvviremicdonorsinkidneytransplantationachanceorathreat
AT baczkowskateresa utilizationofhcvviremicdonorsinkidneytransplantationachanceorathreat
AT durlikmagdalena utilizationofhcvviremicdonorsinkidneytransplantationachanceorathreat